Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)

Clàudia Pla; Marta Solans; Alberto Ameijide; Arantza Sanvisens; Marià Carulla; María Dolores Rojas; María Araceli Alemán; Isabel Sáez-Lloret; Cristina Díaz-Del-Campo; Ana Isabel Marcos-Navarro; Leire Sainz-de-Aja; Amaia Aizpurua-Atxega; Arantza Lopez-de-Munain; Maria-José Sánchez; Josefina Perucha; Paula Franch; María-Dolores Chirlaque; Marcela Guevara; Jaume Galceran; Susana Merino; Rafael Marcos-Gragera; REDECAN working group

doi:10.3389/fonc.2022.1046307

Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)

Front Oncol. 2022 Nov 24:12:1046307. doi: 10.3389/fonc.2022.1046307. eCollection 2022.

Authors

Clàudia Pla^{1

2}, Marta Solans^{3

4}, Alberto Ameijide^{1

2}, Arantza Sanvisens^{5

6}, Marià Carulla^{1

2}, María Dolores Rojas⁷, María Araceli Alemán⁷, Isabel Sáez-Lloret⁸, Cristina Díaz-Del-Campo⁹, Ana Isabel Marcos-Navarro¹⁰, Leire Sainz-de-Aja¹¹, Amaia Aizpurua-Atxega¹¹, Arantza Lopez-de-Munain¹¹, Maria-José Sánchez^{4

12

13

14}, Josefina Perucha¹⁵, Paula Franch^{16

17}, María-Dolores Chirlaque^{4

18}, Marcela Guevara^{4

19

20}, Jaume Galceran^{1

2}, Susana Merino²¹, Rafael Marcos-Gragera^{4

5

6

22}; REDECAN working group

Collaborators

REDECAN working group:
Rm-G, Montse Puigdemont, Anna Vidal Vila, As, Andrés Castillo-Bonilla, Mc, Aa, Cp, Jg, Al-D-M, Patricia Sancho, María Luisa Iruretagoyena, Cristina Ramírez, Sm, Virginia Menéndez García, Marta Rodríguez Camblor, Visitación de Castro, Marta De La Cruz, Joseba Bidaurrazaga, Consol Sabater Gregori, Isabel Sáez Lloret, Ana Vizcaíno Batllés, Xavier Peñalver Herrero, Cd-D-C, Am, Rosario Jimenez Chillarón, Aa, Mdr, Emilio De Miguel, María Carmen Gabas, Mjs, Daysi Yoe-Ling Chang-Chan, Miguel Rodríguez Barranco, María Isabel Palacios, Enrique Ramalle, Paula Franch, Patricia Ruiz Armengol, Carmen Sánchez Contador, Mdc, Antonia Sánchez Gil, Ricardo José Vaamonde, Mg, Eva Ardanaz, Maa, Leonor Olga Velázquez, María Magdalena Ramos Marrero, Pilar Gutiérrez, Rufino Álamo, Lorena Estévez, Adela Cañete, Elena Pardo, Rafael Peris Bonet, Consol Sabater Gregori, Ana Vizcaino Batllés, Fernando Almela Vich

Affiliations

¹ Tarragona Cancer Registry, Cancer Epidemiology and Prevention Service, Sant Joan de Reus University Hospital, Reus, Spain.
² Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Tarragona, Spain.
³ Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain.
⁴ Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
⁵ Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI), Girona, Spain.
⁶ Josep Carreras Leukaemia Research Institute, Girona, Spain.
⁷ Canary Islands Cancer Registry, Public Health Directorate, Canary Islands Government, Las Palmas, Spain.
⁸ Castellón Cancer Registry, Directorate General of Public Health and Addictions, Valencian Government, Castellón, Spain.
⁹ Ciudad Real Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain.
¹⁰ Cuenca Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain.
¹¹ Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain.
¹² Granada Cancer Registry, Andalusian School of Public Health (EASP), Instituto de Investigación Biosanitaria Ibs.GRANADA, University of Granada, Granada, Spain.
¹³ Instituto de Investigación Biosanitaria Ibs.GRANADA, Granada, Spain.
¹⁴ Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
¹⁵ La Rioja Cancer Registry, Epidemiology and Health Prevention Service, Logroño, Spain.
¹⁶ Mallorca Cancer Registry, Public Health and Participation Department, Palma de Mallorca, Spain.
¹⁷ Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
¹⁸ Department of Epidemiology, Regional Health Authority, Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia University, Murcia, Spain.
¹⁹ Navarra Cancer Registry, Navarra Public Health Institute, Pamplona, Spain.
²⁰ Epidemiology and Public Health Area, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
²¹ Department of Health, Asturias Cancer Registry, Public Health Directorate, Asturias, Spain.
²² University of Girona, Girona, Spain.

Abstract

Introduction: The aim of this study was to describe incidence, incidence trends and survival patterns of lymphoid neoplasms (LNs) and its subtypes in Spain in the period 2002-2013 using data from the Spanish Network of Cancer Registries (REDECAN).

Materials and methods: Data were extracted from 13 Spanish population-based cancer registries. LNs incident cases were codified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) and grouped according to the WHO 2008 classification. Age-standardized incidence rates to the 2013 European standard population (ASIRe) were obtained. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype. The number of cases in Spain for 2023 was estimated by applying the estimated age-specific rates for the year 2023 to the 2023 Spanish population. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme method. Sex- and age-specific estimates of 5-year NS were calculated, as well as its changes according to two periods of diagnosis (2002-2007 and 2008-2013).

Results: LNs accounted for 69% (n=39,156) of all hematological malignancies (n=56,751) diagnosed during the period of study. Median age at diagnosis was 67 years (interquartile range (IQR) = 52-77). The overall ASIRe was 34.23 (95% confidence interval (CI): 33.89, 34.57) and showed a marked male predominance in almost all subtypes (global sex ratio = 1.45). During the study period, incidence trends of LNs remained stable (APC: 0.3; 95% CI: -0.1, 0.6), nevertheless some subtypes showed statistically significant variations, such as LNs NOS category (APC: -5.6; 95% CI: -6.8, -4.3). Around 17,926 new cases of LNs will be diagnosed in 2023 in Spain. Survival rates differed considerably across age-groups, while they were similar between men and women. Five- year NS was 62.81% (95% CI: 62.1, 63.52) for all LNs, and varied widely across LNs subtypes, ranging from 39.21% to 90.25%. NS for all LNs improved from the first period of diagnosis to the second one, being 61.57% (95% CI: 60.56, 62.61) in 2002-2007 and 64.17% (95% CI: 63.29, 65.07) in 2008-2013.

Conclusions: This study presents the first complete and extensive population-based analysis of LNs incidence and survival in Spain. These population-based data provide relevant information to better understand the epidemiology of LNs in Southern Europe and it features some useful points for public health authorities and clinicians. However, additional improvements regarding the registration of these hematological neoplasms can be implemented.

Keywords: Spain; incidence; lymphoid neoplasms; population-based; survival; trends.

Copyright © 2022 Pla, Solans, Ameijide, Sanvisens, Carulla, Rojas, Alemán, Sáez-Lloret, Díaz-del-Campo, Marcos-Navarro, Sainz-de-Aja, Aizpurua-Atxega, Lopez-de-Munain, Sánchez, Perucha, Franch, Chirlaque, Guevara, Galceran, Merino, Marcos-Gragera and REDECAN working group.